Other studies of 24-h blood glucose dynamics using continuous glucose monitoring (CGM) reported that SGLT2 inhibitors improve mean blood glucose (MBG) level, postprandial hyperglycemia, and variation in blood glucose level within a few weeks [3–5]. This evidence concerns the gene SLC5A2 and Hyperglycemia.